Why Cellectis' Shares Rose 22.7% This Week
Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The stock closed last Friday at $3.17, then opened Monday at $3.19. It reached its high of $3.97 on Thursday. The stock has a 52-week low of $2.85 and a high of $16.67 and is down more than 53% so far this year.
The company released research data on its new universal CAR (Chimeric Antigen Receptors) T-cell HEAL platform at The American Society of Gene and Cell Therapy's (ASGCT) annual meeting on Monday. In the report, the company said its novel immune-evasive CAR T-cell (ΔTRACCARΔB2MHLAE) showed preclinical promise in fighting acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). The therapy was built using the company's TALEN gene-editing process, whereby healthy stem cells are inserted into the body through an adeno-associated virus.
In the data, the company said that therapy showed efficient anti-tumor activity while evading natural kill cell attacks and the body's natural alloresponsive T-cell attacks that otherwise might dilute its tumor-killing ability.
Source Fool.com
